Schick RR, vorm Walde T, Zimmermann JP, Schusdziarra V, Classen M
The EMA is the European Union counterpart to the FDA in the United States and only applies to semaglutide sold in the EU
It works by activating receptors in the brain, which increase feelings of fullness, reduce hunger, and ultimately lead to a decrease in food intake
The clearest answer to date comes from a Phase 2 trial published in the New England Journal of Medicine in 2023, which reported 24.2% weight loss after 48 weeks at the highest dose in 338 adults with obesity but no other complications
1mg once a week Weeks 13-16: Subcutaneous
Compliance with all storage and dispensing regulations